As applications of generative AI (GenAI), and AI in general, extend to every industry, the dialogue surrounding its responsible integration remains front and centre.
According to Takeda Pharmaceuticals, the average time taken to diagnose a rare disease without technology is 7.6 years, and that comes after countless tests and physician visits.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh